Anti-PD-L1 Immunoconjugates Targeting Inaccessible Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions and methods for delivering antibodies and immune adjuvants are inadequate for reaching inaccessible tumors, limiting treatment options for cancer patients.
Innovation Solution
Development of immunoconjugates comprising an anti-PD-L1 antibody conjugated to 8-cyclyl-2-aminobenzazepine derivatives, which allows for the covalent attachment of a linker to the antibody, enabling targeted delivery to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody delivery methods are used, then treatment simplicity is maintained, but the ability to reach inaccessible tumors is insufficient
Solution Approach 1:
The patent combines an anti-PD-L1 antibody with a cytotoxic agent (8-cyclyl-2-aminobenzazepine derivative) into a single immunoconjugate molecule. The antibody portion targets PD-L1 on tumor cells, while the cytotoxic agent delivers the therapeutic effect directly at the target site, merging targeting and treatment functions into one molecule to reach inaccessible tumors effectively.
Solution Approach 2:
The immunoconjugate represents a composite structure combining two distinct functional components: the antibody moiety for specific recognition and binding to PD-L1, and the cytotoxic 8-cyclyl-2-aminobenzazepine derivative for tumor cell killing. This composite design enables the delivery system to overcome the limitation of conventional methods by integrating targeting precision with potent cytotoxic activity.
2Reliability
If immunoconjugates are developed to target inaccessible tumors, then treatment efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs a linker as an intermediary component that facilitates the conjugation between the antibody and the 8-cyclyl-2-aminobenzazepine derivative. The linker contains reactive functional groups that enable covalent bonding to the antibody while providing stability to the conjugate, thereby simplifying the manufacturing process by mediating the complex conjugation reaction in a controlled manner.
Solution Approach 2:
The patent utilizes changes in chemical reactivity parameters by incorporating a linker with specific reactive functional groups that can form stable covalent bonds with amino acid residues on the antibody. This parameter change approach allows for controlled conjugation under mild conditions, improving ease of manufacture while maintaining treatment efficacy.
3Adaptability or versatility
If conventional treatment options are used, then treatment accessibility is maintained, but cancer treatment options are limited
Solution Approach 1:
The immunoconjugate design provides multi-functionality by combining the targeting capability of the anti-PD-L1 antibody with the cytotoxic activity of the 8-cyclyl-2-aminobenzazepine derivative. This single molecule can target PD-L1 expressing tumors while delivering potent cytotoxic effects, thereby expanding treatment options for cancer patients with inaccessible or resistant tumors without significantly complicating administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoconjugates effectively treat cancer by enhancing immune response and targeting PD-L1 expressing cells, leading to significant tumor regression and immunological memory.
Implementation Method 1
an anti-PD-L1 antibody covalently attached to a linker which is covalently attached to one or more 8-Cyc-2-aminobenzazepine moieties
Data Source
AI summary
The invention provides immunoconjugates of Formula I comprising an anti-PD-L1 antibody linked by conjugation to one or more 8-Cyc-2-aminobenzazepine derivatives. The invention also provides 8-Cyc-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.